Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641557 · ClinicalTrials.gov registry record · Phase 1
A Phase I Dosing Study of IkT-148009.
A Phase 1 study, sponsored by ABLi Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT06641557: Completed Phase 1 study, sponsored by ABLi Therapeutics.
NCT06641557 is a Phase 1 study that has completed, run by ABLi Therapeutics. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06641557, a Phase 1 study, has completed, sponsored by ABLi Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase 1 study in older adult or elderly healthy volunteer subjects to measure the safety, tolerability and pharmacokinetic (PK) profile of IkT-148009 capsules given as multiple capsules.
Primary Outcome
Adverse event reporting
Interventions
- DRUG 200mg of Ikt-148009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 1 |
What the finished NCT06641557 record still lists
NCT06641557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which 200mg of Ikt-148009 is the first listed.
NCT06641557 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06641557 about?
NCT06641557 is a clinical study titled "A Phase I Dosing Study of IkT-148009.". This is a Phase 1 study in older adult or elderly healthy volunteer subjects to measure the safety, tolerability and pharmacokinetic (PK) profile of IkT-148009 capsules given as multiple capsules.
What is the current status of trial NCT06641557?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-02-21. Estimated completion is 2023-04-19.
What interventions are being tested in trial NCT06641557?
The interventions under investigation include: 200mg of Ikt-148009 (DRUG).
Who is sponsoring clinical trial NCT06641557?
This trial is sponsored by ABLi Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06641557's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI